Keros Therapeutics, Inc. (KROS)
11.55
+0.77
(+7.14%)
USD |
NASDAQ |
Aug 25, 14:04
Keros Therapeutics Enterprise Value : -28.14M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -28.14M |
| August 21, 2026 | -23.19M |
| August 20, 2026 | -24.77M |
| August 19, 2026 | -21.80M |
| August 18, 2026 | -31.52M |
| August 17, 2026 | -34.09M |
| August 14, 2026 | -41.63M |
| August 13, 2026 | -30.52M |
| August 12, 2026 | -19.82M |
| August 11, 2026 | -30.92M |
| August 10, 2026 | -29.93M |
| August 07, 2026 | -20.81M |
| August 06, 2026 | -30.72M |
| August 05, 2026 | -43.71M |
| August 04, 2026 | -38.65M |
| August 03, 2026 | -41.43M |
| July 31, 2026 | -42.22M |
| July 30, 2026 | -39.25M |
| July 29, 2026 | -44.20M |
| July 28, 2026 | -42.22M |
| July 27, 2026 | -39.45M |
| July 24, 2026 | -42.42M |
| July 23, 2026 | -40.83M |
| July 22, 2026 | -39.45M |
| July 21, 2026 | -32.31M |
| Date | Value |
|---|---|
| July 20, 2026 | -31.52M |
| July 17, 2026 | -30.92M |
| July 16, 2026 | -31.52M |
| July 15, 2026 | -23.19M |
| July 14, 2026 | -32.31M |
| July 13, 2026 | -21.80M |
| July 10, 2026 | -7.921M |
| July 09, 2026 | -3.361M |
| July 08, 2026 | -10.50M |
| July 07, 2026 | -10.90M |
| July 06, 2026 | -23.19M |
| July 02, 2026 | -18.63M |
| July 01, 2026 | -26.16M |
| June 30, 2026 | -29.73M |
| June 29, 2026 | -49.51M |
| June 26, 2026 | -48.32M |
| June 25, 2026 | -59.77M |
| June 24, 2026 | -49.70M |
| June 23, 2026 | -48.13M |
| June 22, 2026 | -48.52M |
| June 18, 2026 | -55.03M |
| June 17, 2026 | -59.77M |
| June 16, 2026 | -67.27M |
| June 15, 2026 | -63.12M |
| June 12, 2026 | -64.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 21.22B |
| Nurix Therapeutics, Inc. | 2.339B |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.71M |
| Total Expenses (Quarterly) | 28.71M |
| EPS Diluted (Quarterly) | -1.45 |
| Earnings Yield | -32.03% |
| Normalized Earnings Yield | -32.01 |